Stratpharma AG
14
5
5
8
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
7.1%
1 terminated/withdrawn out of 14 trials
88.9%
+2.4% vs industry average
14%
2 trials in Phase 3/4
0%
0 of 8 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (14)
Prevention of Stretch Marks in Expectant Mothers
Role: lead
VALOR: Vaginal Atrophy & Long-term Observation of Recovery
Role: lead
Silicone Gel vs. Estrogen Vaginal Cream for the Management of Genitourinary Syndrome of Menopause
Role: lead
ASSIST-VLA: Assessment of Symptom-Specific Improvement in Diagnosed Vaginal Atrophy Following Laser Therapy
Role: lead
StrataMGT for the Treatment of Vulvar Lichen Sclerosus
Role: collaborator
StrataMGT in the Reduction of Vulvar Lichen Sclerosus (LS) Symptoms
Role: collaborator
StrataXRT Versus Aquaphor for the Prevention and Management of Radiation Dermatitis
Role: lead
Retrospective Cohort Study Comparing a Novel Gel Dressing vs SoC in the Treatment of Radiation Dermatitis
Role: lead
Impact of Silicon-based Formulations on Wound Healing of Laser-induced Microscopic Skin Lesions
Role: lead
StrataXRT vs. Standard Clinical Practice in the Prevention and Treatment of Radiation Dermatitis
Role: lead
An Innovative Silicone Wound Dressing for the Management of Atrophic Vaginitis
Role: lead
a Flexible Wound Dressing for the Management of Genital Skin Conditions
Role: lead
Comparison of a Novel Wound Dressing Stratamed Versus Current Clinical Practice After Follicular Unit Extraction Hair Transplantation
Role: lead
Prevention and Treatment of Stretch Marks With Stratamark™
Role: lead
All 14 trials loaded